Sang­amo splits the R from the D in a re­or­ga­ni­za­tion — and bids chief farewell

A lot of big or grow­ing bio­phar­ma com­pa­nies ask them­selves whether re­search and de­vel­op­ment should be split in­to two sep­a­rate groups or head­ed up by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.